NanoForm Cardiovascular Therapeutics Ltd, London, UK Established for the Further Development and Commercialization of Proprietary NanoActive(TM) Formulations of Two Blockbuster Drugs

BUDAPEST, HUNGARY and LONDON, UNITED KINGDOM--(Marketwire - April 13, 2010) - NanGenex Inc. the Proprietary NanoActive™ Continuous Flow Technology Platform company today announced the establishment of NanoForm Cardiovascular Therapeutics Ltd, London, UK for the further development and commercialization of proprietary NanoActive™ formulations of two blockbuster drugs for cardiovascular indications.

“This is a major milestone in the development of a new class of innovative Nanodrugs that provide fundamental improvements and clinically meaningful benefits over the original drug formulations. NanoForm Cardiovascular Therapeutics has acquired all rights to the two proprietary NanoActive™ formulations. It is in advanced discussions with strategic investors and pharmaceutical partners to bring these breakthrough products to the market” - said Dr. Ferenc Darvas, Founder and the President of the Board.

“We are very excited about the great results we have generated with the two NanoActive™ formulations. It has once again showed the significant benefit that can be achieved with the NanoActive™ technology. The unique nanostructured particle formation will be applicable for many established drugs with limited solubility and or permeability to transform them into instantaneously redispersable form with increased solubility. Moreover, the virtual high throughput nanoparticle drug delivery technology enables us to design and produce nanostructured pharmaceutical macromolecules (e.g.; polypeptides, polynucleotides) and highly stable nanostructured particles for prolonged release injectable formulations” - explained Gabor Heltovics, CEO of NanGenex.

About NanGenex Inc.

NanGenex is a Proprietary NanoActive™ Continuous Flow Technology Platform company based and anchored as a member of the oldest and largest technology corporation network in Hungary which was established more than 25 years ago. It provides breakthrough solutions to develop new generations of NanoActive™ products with significant performance benefits over conventional approaches. The company has a unique platform of proprietary technology solutions encompassing the full R&D and commercialization value chain from upstream research and discovery to full scale product manufacturing and commercialization.

More information about NanGenex can be found at www.nangenex.com.